Accropeutics Inc. Announces U.S. FDA Clearance of IND Application for RIPK2 Inhibitor AC-101

Accropeutics Inc. Announces U.S. FDA Clearance of IND Application for RIPK2 Inhibitor AC-101

Company to conduct a Phase II multi-regional clinical trial (MRCT) for the treatment of Ulcerative Colitis (UC) A Phase Ib Study of AC-101 for Ulcerative Colitis (UC) has been initiated in China AC-101 demonstrated a favorable safety and PK/PD...

menu
menu